News Quantified

CSBR – champions oncology, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Champions Oncology (NASDAQ:CSBR) shareholders have endured a 61% loss from investing in the stock three years ago [Yahoo! Finance]

Champions Oncology Announces Agreement with Weill Cornell Medicine [Yahoo! Finance]

Champions Oncology Announces Agreement with Weill Cornell Medicine

Champions Oncology (NASDAQ:CSBR) Is In A Strong Position To Grow Its Business [Yahoo! Finance]

Champions Oncology, Inc. (CSBR) Q1 2025 Earnings Call Transcript [Seeking Alpha]

5.4%

BEAT

Form 4 CHAMPIONS ONCOLOGY, INC. For: Nov 12 Filed by: Breitfeld Philip P.

Form 4 CHAMPIONS ONCOLOGY, INC. For: Nov 12 Filed by: SIDRANSKY DAVID

Form 4 CHAMPIONS ONCOLOGY, INC. For: Nov 12 Filed by: Mendelson Daniel Newman

Form 4 CHAMPIONS ONCOLOGY, INC. For: Nov 12 Filed by: TOBIN SCOTT R

Form 4 CHAMPIONS ONCOLOGY, INC. For: Nov 12 Filed by: ACKERMAN JOEL

Top News Gainers

3/12 Form 8-K CHAMPIONS ONCOLOGY, INC. For: Jan 31 36.8%

9/5 Form 8-K CHAMPIONS ONCOLOGY, INC. For: Sep 05 9.4%

10/16 Form 8-K CHAMPIONS ONCOLOGY, INC. For: Oct 16 7.2%

3/30 Form 4 CHAMPIONS ONCOLOGY, INC. For: Mar 26 Filed by: Mendelson Daniel Newman 6.3%

3/16 Form 10-Q CHAMPIONS ONCOLOGY, INC. For: Jan 31 5.3%

3/27 Champions Oncology Inc (NASDAQ: CSBR) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 4.8%

12/4 Form 4 CHAMPIONS ONCOLOGY, INC. For: Dec 02 Filed by: ACKERMAN JOEL 4.4%

3/24 Form 4 CHAMPIONS ONCOLOGY, INC. For: Mar 20 Filed by: Morris Ronnie 4.3%

9/16 Form 10-Q CHAMPIONS ONCOLOGY, INC. For: Jul 31 3.7%

1/22 Champions Oncology Inc (NASDAQ: CSBR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.25 price target on the stock. 3.7%

Top News Decliners

12/16 Form 8-K CHAMPIONS ONCOLOGY, INC. For: Dec 16 -18.8%

7/15 Champions Oncology Reports Record Quarterly Revenue of $7.7 Million For The Fourth Quarter Ended April 30, 2019 -15.2%

9/16 Q1/2020 7/31/2019 EPS -0.060 ZacksConsensus 0.040 ActVsEst (0.100) - Miss -14.2%

3/17 Champions Oncology Inc (NASDAQ: CSBR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $5.50 price target on the stock. -12.2%

3/10 Form 4 CHAMPIONS ONCOLOGY, INC. For: Mar 06 Filed by: Sonsini Peter W. -7.5%

3/10 Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 12, 2020 -6.5%

8/28 Form DEF 14A CHAMPIONS ONCOLOGY, INC. For: Apr 30 -5.1%

11/18 Champions Oncology Inc (NASDAQ: CSBR) is now covered by analysts at Benchmark Co.. They set a "buy" rating on the stock. -5.0%

3/12 Form 4 CHAMPIONS ONCOLOGY, INC. For: Mar 11 Filed by: TABORS R DAVID -3.9%

11/27 Champions Oncology Inc (NASDAQ: CSBR) is now covered by analysts at Benchmark Co.. They set a "buy" rating and a $11.00 price target on the stock. -3.3%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day